Teleflex Incorporated
TFXTeleflex Incorporated (TFX) is a global provider of medical technologies focused on solutions for healthcare providers and patients. Founded in 1943, the company specializes in products used in minimally invasive surgeries, anesthesiology, respiratory care, and vascular access, offering a broad portfolio aimed at improving clinical outcomes and healthcare efficiency. Its innovations support hospitals, clinics, and other medical facilities worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 15, 2025 | $0.34 | 2025-11-14 | 2025-11-14 |
| September 15, 2025 | $0.34 | 2025-08-15 | 2025-08-15 |
| June 16, 2025 | $0.34 | 2025-05-20 | 2025-05-20 |
| March 17, 2025 | $0.34 | 2025-03-07 | 2025-03-07 |
| December 16, 2024 | $0.34 | 2024-11-15 | 2024-11-15 |
Dividends Summary
- Consistent Payer: Teleflex Incorporated has rewarded shareholders with 89 dividend payments over the past 22 years.
- Total Returned Value: Investors who held TFX shares during this period received a total of $28.84 per share in dividend income.
- Latest Payout: The most recent dividend of $0.34/share was paid 39 days ago, on December 15, 2025.
- Yield & Schedule: TFX currently pays dividends quarterly with an annual yield of 1.29%.
- Dividend Growth: Since 2003, the dividend payout has grown by 70.0%, from $0.20 to $0.34.
- Dividend Reliability: TFX has maintained or increased its dividend for 89 consecutive payments.
Company News
The global synthetic absorbable sutures market is valued at USD 2.51 billion in 2025 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 7.19%. Growth is driven by rising surgical volumes, increasing adoption of minimally invasive procedures, and advancements in polymer technology. However, higher costs compared to convention...
The global catheters market is projected to grow from USD 29.17 billion in 2025 to USD 55.58 billion by 2033, with a CAGR of 8.41%. Growth is driven by increasing cardiovascular and urological procedures, aging populations, and technological advancements. However, catheter-associated infections and antibiotic resistance pose challenges. North Ame...
The global pulmonary function testing market is projected to grow from USD 3.39 billion in 2025 to USD 5.66 billion by 2033, with a CAGR of 6.65%. Growth is driven by rising prevalence of chronic respiratory diseases, an aging population, and technological advancements in diagnostic devices. The U.S. market is expected to expand from USD 1.03 bil...
The global disposable endoscopes market is expected to grow from USD 2.6 billion in 2024 to USD 5.7 billion by 2032, driven by healthcare providers' focus on infection control, minimally invasive procedures, and technological advancements. North America leads the market, while Asia-Pacific is expected to experience the fastest growth. Key players...
Coloplast announces leadership transitions, with Dorthe Rønnau leaving People & Culture and Tommy Johns retiring from Urologi. Kevin Hardage will join as new Urologi leader, bringing extensive medtech experience.
